Non Alcoholic Fatty Liver Disease (NAFLD) – Drugs in Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non Alcoholic Fatty Liver Disease – Drugs in Development, 2021, provides an overview of the Non Alcoholic Fatty Liver Disease (Gastrointestinal) pipeline landscape.

Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease. Nonalcoholic fatty liver disease is common and, for most people, causes no signs and symptoms and no complications. But in some people with non-alcoholic fatty liver disease, the fat that accumulates can cause inflammation and scarring in the liver. The most common symptoms that bring NAFLD to medical attention are malaise, fatigue, and right upper quadrant or diffuse abdominal discomfort.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non Alcoholic Fatty Liver Disease – Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Non Alcoholic Fatty Liver Disease (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non Alcoholic Fatty Liver Disease (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 29, 16, 2, 43 and 13 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 7 molecules, respectively.

Non Alcoholic Fatty Liver Disease (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Non Alcoholic Fatty Liver Disease (Gastrointestinal).

– The pipeline guide reviews pipeline therapeutics for Non Alcoholic Fatty Liver Disease (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Non Alcoholic Fatty Liver Disease (Gastrointestinal) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Non Alcoholic Fatty Liver Disease (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Non Alcoholic Fatty Liver Disease (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Non Alcoholic Fatty Liver Disease (Gastrointestinal).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Non Alcoholic Fatty Liver Disease (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

89bio Inc

ABIONYX Pharma SA

Afimmune Biopharma Ltd

Albireo Pharma Inc

Alfasigma SpA

Amicogen Inc

AptamiR Therapeutics Inc

Ascletis Pharma Inc

AstraZeneca Plc

Azure Health Technology Ltd

Bast Biotechnology LLC

Bausch Health Companies Inc

BBN Cardio Therapeutics

Table of Contents

Table of Contents

Introduction

Non Alcoholic Fatty Liver Disease (NAFLD) - Overview

Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics Development

Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics Assessment

Non Alcoholic Fatty Liver Disease (NAFLD) - Companies Involved in Therapeutics Development

Non Alcoholic Fatty Liver Disease (NAFLD) - Drug Profiles

Non Alcoholic Fatty Liver Disease (NAFLD) - Dormant Projects

Non Alcoholic Fatty Liver Disease (NAFLD) - Discontinued Products

Non Alcoholic Fatty Liver Disease (NAFLD) - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Companies, 2021 (Contd..1)

Number of Products under Development by Companies, 2021 (Contd..2)

Number of Products under Development by Companies, 2021 (Contd..3)

Number of Products under Development by Companies, 2021 (Contd..4)

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Products under Development by Companies, 2021 (Contd..2)

Products under Development by Companies, 2021 (Contd..3)

Products under Development by Companies, 2021 (Contd..4)

Products under Development by Companies, 2021 (Contd..5)

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Target, 2021 (Contd..1)

Number of Products by Stage and Target, 2021 (Contd..2)

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Mechanism of Action, 2021 (Contd..1)

Number of Products by Stage and Mechanism of Action, 2021 (Contd..2)

Number of Products by Stage and Mechanism of Action, 2021 (Contd..3)

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by 89bio Inc, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by ABIONYX Pharma SA, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Afimmune Biopharma Ltd, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Albireo Pharma Inc, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Alfasigma SpA, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Amicogen Inc, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by AptamiR Therapeutics Inc, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Ascletis Pharma Inc, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by AstraZeneca Plc, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Azure Health Technology Ltd, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Bast Biotechnology LLC, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Bausch Health Companies Inc, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by BBN Cardio Therapeutics, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Beijing Fogangren Bio-Pharm Tech Co Ltd, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Betagenon AB, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Bird Rock Bio Inc, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Bristol-Myers Squibb Co, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Cadila Healthcare Ltd, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Can-Fite BioPharma Ltd, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Carmot Therapeutics Inc, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by ChemomAb Ltd, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by China NT Pharma Group Co Ltd, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by CohBar Inc, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Corcept Therapeutics Inc, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Dr. Falk Pharma GmbH, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by DURECT Corp, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Eli Lilly and Co, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Eternygen GmbH, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Evgen Pharma Plc, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by F. Hoffmann-La Roche Ltd, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Fujian Cosunter Pharmaceutical Co Ltd, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Future Medicine Co Ltd, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Galmed Pharmaceuticals Ltd, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by GemVax & KAEL Co Ltd, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Gilead Sciences Inc, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Hanmi Pharmaceuticals Co Ltd, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Hepion Pharmaceuticals Inc, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by HighTide Therapeutics Inc, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by HK inno.N Corp, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by HysensBio Corp, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Immuron Ltd, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Inmune Bio Inc, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Inorbit Therapeutics AB, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Inventiva, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Ionis Pharmaceuticals Inc, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by J2H Biotech, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Kaleido Biosciences Inc, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Kinomedica Pty Ltd, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by KoBioLabs Inc, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Kowa Co Ltd, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Kyorin Pharmaceutical Co Ltd, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Liminal BioSciences Inc, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Lipidio Pharmaceuticals Inc, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Macrophage Pharma Ltd, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Macrophage Therapeutics Inc, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Mallinckrodt Plc, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Metacrine Inc, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Micelle BioPharma Inc, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Mina Therapeutics Ltd, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Nano Intelligent Biomedical Engineering Corp, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by NGM Biopharmaceuticals Inc, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Nivarta Inc, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Novartis AG, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by NovMetaPharma Co Ltd, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by NuSirt Biopharma Inc, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Oncocross Co Ltd, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by PegBio Co Ltd, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Pfizer Inc, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by PharmaKing Co Ltd, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Phenex Pharmaceuticals AG, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by PTC Therapeutics Inc, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Renova Therapeutics Inc, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Salix Pharmaceuticals Ltd, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by SparkBioPharma Inc, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Sveikatal Inc, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by T3D Therapeutics Inc, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by TaiwanJ Pharmaceuticals Co Ltd, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by TES Pharma SRL, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Theratechnologies Inc, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Uni-Bio Science Group Ltd, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Vidasym Inc, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Viking Therapeutics Inc, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Dormant Projects, 2021

Non Alcoholic Fatty Liver Disease (NAFLD) – Dormant Projects, 2021 (Contd..1)

Non Alcoholic Fatty Liver Disease (NAFLD) – Dormant Projects, 2021 (Contd..2)

Non Alcoholic Fatty Liver Disease (NAFLD) – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD), 2021

Number of Products under Development by Companies, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports